TickerFacts.

MapLight Therapeutics, Inc. (MPLT): R&D Expense

Annual figures by period end, from SEC filings.

$138.35M
Year ended 2025-12-31
$198.84M
Trailing 12 months to 2026-06-30
2024-12-31: $68.52M2025-12-31: $138.35M$138.35M
2024-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$138.35M+101.9%2026-03-26, From 2025-01-01
2024-12-31$68.52Mn/a2026-03-26, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
MapLight Therapeutics, Inc. (MPLT)2025-12-31$138.35M+101.9%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$167.34M-29.7%
Enliven Therapeutics, Inc. (ELVN)2025-12-31$85.86M+6.3%
Theravance Biopharma, Inc. (TBPH)2025-12-31$37.41M-0.6%
Oruka Therapeutics, Inc. (ORKA)2025-12-31$100.64Mn/a
Vanda Pharmaceuticals Inc. (VNDA)2025-12-31$109.27M+46.8%
Ardelyx, Inc. (ARDX)2025-12-31$71.53M+36.7%
Biohaven Ltd. (BHVN)2025-12-31$635.07M-20.2%
Rapport Therapeutics, Inc. (RAPP)2025-12-31$94.79M+55.6%

Compare MPLT, RYTM, ELVN, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗